Aurobindo Pharma announced that the United States Food and Drug Administration (US FDA) inspected Unit-V, an API manufacturing facility, of Apitoria Pharma, a wholly owned subsidiary of the Company, situated at Industrial Development Area, Chemical Zone, Pashamylaram Village, Patancheru Mandal, Sangareddy District, 502307, Telangana from 01 December to 12 December 2025. At the end of the inspection, a `Form 483` was issued with 03 observations. The Unit has now received an Establishment Inspection Report (EIR) classifying the facility as `Voluntary Action Indicated` (VAI) and this inspection is now �closed�. Powered by Capital Market - Live News

Eugia Pharma Specialities, a wholly owned subsidiary of Aurobindo Pharma, has launched Pomalidomide Capsules, 1 mg, 2 mg, 3 mg and 4 mg, in the US market. The product is the generic equivalent of Pomalyst� Capsules, 1 mg, 2 mg, 3 mg and 4 mg, of BMS Pharmaceuticals Corp. Eugia Pharma Specialities was one of the First-to-File (FTF) ANDA applicants for this product. The product will be manufactured at Eugia Unit-I. According to IQVIA MAT data for the twelve months ending January 2026, Pomalidomide Capsules have an estimated market size of approximately US$ 3.3 billion in the U.S. Pomalidomide is a third-generation immunomodulatory drug (IMiD) used in combination with dexamethasone (and sometimes bortezomib) to treat relapsed or refractory multiple myeloma and AIDS-related Kaposi sarcoma.Powered by Capital Market - Live News

Aurobindo Pharma announced that its wholly owned subsidiary, Eugia Pharma Specialities, has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Everolimus Tablets, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, which is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Zortress Tablets, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, of Novartis Pharmaceuticals Corp.This approval has been received from Eugia Unit-I and is expected to be launched in Q1FY27.The approved product has an estimated market size of US$ 78 million for the twelve months ending December 2025, according to IQVIA MAT. This is the 184th ANDA approval (including 10 tentative approvals received) out of Eugia Pharma Specialities Group (EPSG) facilities, manufacturing both oncology oral and sterile specialty products.Everolimus Tablets are Indicated for the prophylaxis of organ rejection in adult patients (i) Kidney Transplant: at low-moderate immunologic risk. Use in combination with basiliximab, cyclosporine (reduced doses) and corticosteroids (ii) Liver Transplant: Administer no earlier than 30 days posttransplant. Use in combination with tacrolimus (reduced doses) and corticosteroids. Powered by Capital Market - Live News

Net profit of Aurobindo Pharma rose 7.62% to Rs 910.29 crore in the quarter ended December 2025 as against Rs 845.81 crore during the previous quarter ended December 2024. Sales rose 9.01% to Rs 8604.51 crore in the quarter ended December 2025 as against Rs 7893.15 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales8604.517893.15 9 OPM %20.6119.99 - PBDT1868.581618.38 15 PBT1403.851199.85 17 NP910.29845.81 8 Powered by Capital Market - Live News

The board of Aurobindo Pharma at its meeting held on 09 February 2026 has approved a proposal to file a scheme of amalgamation for merger of Auro Vaccines, a wholly owned step-down subsidiary of the Company with Curateq Biologics, a wholly owned subsidiary of the Company, with Hon`ble NCLT, Hyderabad. Powered by Capital Market - Live News